The new Clinical Trial Application for the conduct of a Phase I/II study of RVU120 (SEL120) in patients with solid tumors submitted by Ryvu Therapeutics S.A.
Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be published at American Society of Hematology (ASH) Annual Meeting
Introduction of the Series I Shares to trading on the main market operated by the WSE and designation of the last day of listing of Rights to Series I Shares
Determination of the issue price of Series I shares issued by Ryvu Therapeutics S.A., the number of Series I shares to be offered for subscription by Ryvu Therapeutics S.A. and execution of the pricing supplement to the placement agreement
Ryvu Therapeutics S.A. concludes a placement agreement and commences the book-building process for an offering by way of private subscription of new Series I ordinary bearer shares issued by Ryvu Therapeutics S.A.
